|
Pharmacy -
Pharma Industry - Biotech Industry
|
|
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced that its Phase III study on intravenous ibuprofen as a post-operative analgesic was published in Volume 31, Number 9 of the peer-reviewed journal Clinical Therapeutics, distributed in October. The study concludes that patients emerging from orthopedic and abdominal surgeries required less narcotic and experienced less pain with 800 mg of intravenous ibuprofen every six hours compared to morphine alone. Read more:
|
